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Domains Protein 2
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The commensal bacterium Enterococcus faecalis is a common cause of nosocomial infections 
worldwide. The increasing prevalence of multi-antibiotic resistant E. faecalis strains reinforces this 
public health concern. Despite numerous studies highlighting several pathology-related genetic traits, 
the molecular mechanisms of E. faecalis virulence remain poorly understood. In this work, we studied 
23 bacterial proteins that could be considered as virulence factors or involved in the Enterococcus 
interaction with the host. We systematically tested their interactions with human proteins using 
the Human ORFeome library, a set of 12,212 human ORFs, in yeast. Among the thousands of tested 
interactions, one involving the E. faecalis virulence factor ElrA and the human protein FHL2 was 
evidenced by yeast two-hybrid and biochemically confirmed. Further molecular characterizations 
allowed defining an FHL2-interacting domain (FID) of ElrA. Deletion of the FID led to an attenuated in 
vivo phenotype of the mutated strain clearly indicating that this interaction is likely to contribute to the 
multifactorial virulence of this opportunistic pathogen. Altogether, our results show that FHL2 is the 
first host cellular protein directly targeted by an E. faecalis virulence factor and that this interaction is 
involved in Enterococcus pathogenicity.
Enterococcus faecalis belongs to the human core intestinal microbiota, i.e the limited number of species that are 
shared by more than 50% of the population1. Although it is a common inhabitant of our intestinal tract, E. faecalis 
is also a major opportunistic pathogen for critically ill or immuno-compromised patients2, 3. Indeed, E. faecalis is 
ranked among the most common nosocomial pathogens worldwide infecting the bloodstream and urinary tract. 
Understanding the molecular mechanisms of E. faecalis pathogenicity is therefore crucial to design new therapeu-
tic approaches to treat enterococcal infections even when strains resistant to antibiotics are involved. E. faecalis 
does not harbour virulence factors such as effectors and toxins identified in Gram-positive pathogens. Instead, 
the pathogenicity of E. faecalis relies on a multifactorial process that involves biofilm formation, antibiotic4, 5 and 
stress resistances6–8, adhesion to host cells and intracellular survival3.
Several E. faecalis surface exposed proteins involved in different processes are likely to contribute to bacte-
rial pathogenicity e.g., adhesion to host cells, host cell invasion and bacterial protection against host defenses. 
Except for the enterococcal fibronectin-binding protein A (EfbA)9, most of these surface exposed proteins pos-
sess a surface-exposure motif (anchoring or retention motif) such as the WxL domain like of the enterococcal 
leucine-rich protein A (ElrA)10 or a LPxTG-anchored domain as for the aggregation substance (AS) proteins11, 
adhesin to collagen (Ace)12, Ebp pilus13, 14, the FSS15, and PrgB16 proteins.
These E. faecalis surface exposed proteins were reported as targeting different host extracellular matrix 
proteins. Among the members of the AS (aggregation substances) proteins, Asa1 interacts with intestinal 
epithelial cell lines, macrophages and neutrophils via its binding to CD11b/CD18 integrin, fibronectin and 
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thrombospondin17, 18. Ace is characterized by adjacent immunoglobulin-like folds that define the family of 
Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) and it interacts with 
collagen type I and laminin12, 19. The anchorless EfbA protein binds fibronectin9. Finally, Ebp pili adhere to fibrin-
ogen, collagen, and to platelets14, 20. Overall, these proteins or complexes seem to have multifunctional roles, 
suggesting that they may interact with different host-cell unknown components through different functional 
domains.
To extend our knowledge on the mechanisms developed by E. faecalis to interact with its host, we used a sys-
tematic high-throughput yeast two-hybrid (HT-Y2H) approach to identify protein interactions between selected 
surface protein of this bacterium and the human proteome. Such screening approaches were successfully used 
with pathogenic microbes, including bacteria such as Brucella21 or Pseudomonas syringae22 and viruses such as 
Epstein-Barr23, Hepatitis C24, HTLVs25, or dengue fever virus26. Here, we report the systematic screening for inter-
actions between 23 selected E. faecalis proteins and the human ORFeome v3.1 (hORFeome), and the identifica-
tion of a specific interaction between the E. faecalis ElrA and the human FHL2, a member of the Four-and-a-Half 
LIM Domains Protein family. Disruption of this interaction led to an impairment of the in vivo pathogenic phe-
notype strongly suggesting a role of this newly identified interaction in the E. faecalis-host interplay.
Results
Selection of 23 E. faecalis ORFs. We defined three criteria based on previous publications in the field of 
host-bacteria interactions to select 23 proteins expressed by E. faecalis and that could promote interaction with 
the host namely proteins harbouring a putative surface-exposure motif (anchoring or retention motif) and/or a 
eukaryotic-like domain and proteins already described as involved in E. faecalis virulence (Table 1 and Fig. 1).
Based on sequence analysis, we first selected 12 surface exposed proteins known to be involved in E. faeca-
lis virulence: 10 containing an LPxTG anchoring domain (EbpA, EbpB, EbpC, Ace, Fss1, Fss2, Fss3, EF3314, 
Asa1 and PrgB), 1 containing a WxL retention domain (ElrA) and 1 anchorless protein (EfbA). It is well estab-
lished that cell surface anchored proteins are involved in bacterial-host interactions and that in pathogens, they 
are often required for the first steps of infection by promoting the interaction with the host targeted cells27–29. 
Moreover, these surface exposed virulence factors have either prokaryotic or eukaryotic-like domains, which 
can be involved in interaction with the host components (Table 2). Based on these data, we selected 11 additional 
E. faecalis proteins that have surface anchors and/or eukaryotic-like domains but which are not integral mem-
brane proteins that were excluded to avoid false positive hit due to hydrophobic regions in the Y2H screen30, 31. 
EF gene Other name Vir factor Domains Retention
EF1092 EbpB 69 Cna_B repeat domain LPxTG
EF1249 EfbA (FbpA-like) 9, 70 Fibronectin binding d (pfam05833) —
EF1093 EbpC 9 Cna_B repeat domain LPxTG
EF1099 Ace 71 Collagen binding domain LPxTG
EF2686 ElrA 10 LRR (COG4886) WxL
EF1896 Fss3 15 Cna_B repeat domain LPxTG
EF1091 EbpA 69 Willebrand factor (vWA) Cna_B repeat domain LPxTG
EFB0011 PrgB 16 Glucan binding dom (pfam08363) Antigen_C (pfam16364) LPxTG
EFA0047 Asa1 17 Glucan binding dom (pfam08363) Antigen_C (pfam16364) LPxTG
EF2505 Fss2 15 BIG3 domain Cna_B repeat domain LPxTG
EF3314 — 72 LPxTG
EF0089 Fss1 15 Collagen binding dom (pfam5737) Cna_B repeat domain LPxTG
EF2713 — no E. faecalis specific protein LPxTG
EF2250 — no LRR (COG4886) WxL
EF2525 (phage like prot) no E. faecalis specific protein LPxTG
EF0775 EbsG no Willebrand factor (vWA) LPxTG
EF0149 PrgB-like no Glucan binding dom (pfam08363)Antigen_C (pfam16364) LPxTG
EF0485 AS (agreg subs) no Glucan binding dom (pfam08363) Antigen_C (pfam16364) LPxTG
EF2224 — no LPxTG
EF0592 — no LPxTG
EF2090 — no Collagen domain (pfam01391) —
EF0377 — no Ankyrin domains (pfam00023) —
EF0286 — no Fibronectin binding (pfam07299) —
Table 1. Description of the 23 E. faecalis selected ORFs.
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The additional selected E. faecalis proteins were: EF2525, EF2713, EF2250, EbsG, Prg-B-like, EF0485, EF2224, 
EF0592, EF2090, EF0377, EF0286.
Altogether, we selected a set of 19 potentially surface exposed proteins (Fig. 1 and Table 1): 16 proteins con-
tain an LPxTG anchoring domain, 2 proteins have a WxL retention domain and 1 is an anchorless protein. 
LPxTG-proteins EF2525 and EF2713 exhibiting neither predicted domain nor homology with other bacterial 
proteins were selected and can be considered as E. faecalis specific proteins. The 17 other proteins contained 
either prokaryotic or eukaryotic-like domains likely to promote protein-protein interactions. The prokar-
yotic domains are: (i) the Glucan binding domain and Antigen_C (PrgB, Asa1, PrgB-like and EF0485), (ii) a 
collagen- or fibronectin-binding domain (Fss1, Ace and EfbA) and (iii) the Leucine rich repeat (LRR) domain 
(ElrA and EF2250) interaction. Regarding the eukaryotic-associated motif, we found the von Willebrand fac-
tor type A (vWA) domain that was originally found in the blood coagulation protein von Willebrand factor 
(vWF), a signature of adhesion in eukaryotes present in EbsG and EbpA, two Ig-like fold domains (i) the bacterial 
immunoglobulin-like BIG3 domain detected in EF2505 and (ii) the Cna_B repeat detected in 6 E. faecalis proteins 
(EbpA, EbpB, EbpC, Fss1, Fss2 and Fss3). Note that the Fss proteins 1 to 3 have been shown to bind fibrinogen15. 
Three proteins exhibiting the ankyrin repeat, fibronectin binding or collagen eukaryotic-like domains were also 
selected. EF0377 displays 4 ankyrin domains. The ankyrin domains have been shown to promote specific inter-
actions with host proteins leading to the impairment of the targeted molecule activity. Many examples demon-
strated the role of ankyrin repeat bacteria effectors in the hijacking of eukaryotic functions by the pathogen 
during the infection process32. EF0286 and EF1249 have a fibronectin-binding domain (pfam07299 that enables 
adhesion of the bacteria to the host tissues. EF2090 exhibits collagen domains involved in protein interactions of 
fiber structures.
The selected set of 23 E. faecalis proteins, harbour particular domains that are likely to be involved in the inter-
action of the bacterium with the host and are summarized in Table 1 and Fig. 1.
Identification of ElrA FHL interactions using HT-Y2H. The interactions between the 23 selected E. fae-
calis putative virulence factors and the Human proteome were tested using the yeast two-hybrid approach33. The 
23 E. faecalis ORFs were amplified by nested PCR amplification34, cloned in the pDONR223 using the Gateway 
system and transferred in the pDestDB-GW vector (see Material and Methods) prior to interactomic assays. Each 
selected E. faecalis ORFs was tested with the human ORFeome v3.1 containing 12,212 human ORFs35, 36. Among 
the 280,876 tested interactions, a single protein out of the 23 tested gave positive hits. The candidates interacting 
pairs of proteins were identified, revealing ElrA10, interacted with 3 human ORFs: FHL2 (31042@A08), GOPC 
(11063@H10) and CDC23 (11088@H06). The interactions were individually validated by mating the yeast strains 
carrying ElrA fused to the Gal4 DNA binding domain (BD) and the human ORFs flanked by the Gal4 Activating 
Domain (AD) and growing them on medium selecting for strong interactions. The interaction of ElrA with FHL2 
was the only one confirmed. FHL2 is a member of the four-and-a-half-LIM protein family, known to partici-
pate in many cellular processes37 and including FHL1, FHL2, FHL3, FHL4 and FHL5/ACT in humans. The LIM 
domain is a highly conserved double zinc-finger motif38.
Figure 1. Representation of the E. faecalis set of proteins with their domains. The proteins are designed 
by their EF numbers; some of them were also published with the following names: EF1092: EbpB, EF1093: 
EbpC, EF1099: Ace, EF2686: ElrA, EF0775: EbsG, EF1896: Fss3, EF1091: EbpA, EFB0011: PrgB, EFA0047: 
Asa1, EF0149: PrgB-like, EF0485: AS, EF0089: Fss1, EF1249: EfbA. Additional information on expression or 
homology of the protein are shown as follows: *enriched in clinical isolates; **induced in the gastrointestinal 
tract; °aggregation substance-like; #phage-like protein; §FbpA like protein.
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The hORFeome contains 5 different FHL sequences: FHL1 843 ncl (11050@D04), FHL2 840 ncl (31042@A08), 
FHL3 843 ncl (11031@C01), FHL3 519 ncl (11018@E03) a truncated variant of FHL3 and FHL5 855 ncl (11050@
F02). In the same experimental set-up we tested the individual interaction of each clone with the ElrA protein. In 
stringent selective conditions, the interaction was only detected for FHL2 (Fig. 2). As no interaction was detected 
between ElrA and the other FHL family members, we concluded that in the Y2H assay, ElrA interacts specifically 
with FHL2.
Strain Relevant Genotype or Description Reference or Source
E. coli
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(StrR) endA1 λ- Invitrogen corporation
DB3.1 ccdB resistant cloning strain F- gyrA462 endA1 glnV44 Δ(sr1-recA) mcrB mrr hsdS20(rB-, mB-) ara14 galK2 lacY1 proA2 rpsL20(Smr) xyl5 Δleu mtl1 Invitrogen corporation
ER2566 F- λ- fhuA2 (lon) ompT lacZ::T7 gene 1 gal sulA11 Δ(mcrC-mrr)114::IS10 R(mcr-73::miniTn10-TetS)2 R(zgb-210::Tn10)(TetS) endA1 (dcm) Invitrogen corporation
S. cerevisiae
Y8800 MATa leu2–3,112 trp1–901 his3Δ200 ade2–101 gal4Δ gal80Δ cyh2R GAL2::ADE2 GAL1::HIS3@LYS2 GAL7::LacZ@met2 62
Y8930 MATα leu2–3,112 trp1–901 his3Δ200 ade2–101 gal4Δ gal80Δ cyh2R GAL2::ADE2 GAL1::HIS3@LYS2 GAL7::LacZ@met2 62
E. faecalis
V583 (VE14002) Hospital strain, VanR 73
OG1RF (VE14001) Plasmid-cured derivative from human oral cavity, Fusr Rifr; 74
VE14201 OG1RF strain, ΔelrA mutant 10
VE18355–3 OG1RF strain, elrAΔFID mutant 1 this study
VE18355-4 OG1RF strain, elrAΔFID mutant 2 this study
Plasmid Description Reference or source
pDONR223 Spectinomycin resistant cloning vector Invitrogen corporation
pDestAD-GW-CYH Single copy plasmid allowing Gal4 activation domain (AD) hybrid proteins fusion 60
pDestDB-GW single copy plasmid allowing Gal4 DNA binding domain (DB) hybrid proteins fusion 60
pGEX-2TK-GW GST fusion vector Gateway-compatible 21
pCMVHA-GW pCMVHA (Clontech) Gateway-compatible 21
pCMVmyc-GW pCMVmyc (Clontech) Gateway-compatible 64
pV1899 pCMV 5′ Triple Flag Nterm Gateway-compatible 61
pGEM-T Easy T vector with f1 oriR, ApR Promega corporation
pG+host9 66
pDONR-EF2686 pDONR223 carrying EF2686 (elrA) this study
pDestDB-EF2686 pDestDB carrying EF2686 (elrA) this study
pDONR-FHL1 pDONR223 carrying FHL1 (hORF 11050@D04) 35
pDONR-FHL2 pDONR223 carrying FHL2 (hORF 31042@A08) 36
pDONR-FHL3 pDONR223 carrying FHL3 (hORF 11031@C01) 35
pDONR-FHL3-Cter pDONR223 carrying FHL3 (hORF 11018@E03) 35
pDONR-FHL5 pDONR223 carrying FHL5 (hORF 11050@F02) 35
pDONR-GOPC pDONR223 carrying GOPC (hORF 11063@H10) 35
pDONR-CDC23 pDONR223 carrying CDC23 (hORF 11088@H06) 35
pDONR-EFXXXX pDONR223 carrying EFXXXX this study
pDONR-ElrAabc-xyz
pDONR223 carrying the elrAfragment (corresponding to amino acid abc to xyz) 
amplified with primers ElrA_FX and ElrA_RX this study
pDB-ElrAabc-xyz pDestDB carrying elrA transfered by LR reaction from pDON-ElrAabc-xyz this study
pGEX-ElrA27-723 pGEX-2TK-GW carrying the elrA fragment transfered from pDONR-ElrA27–723 this study
pGEX-ElrA27–473 pGEX-2TK-GW carrying the elrA fragment transfered from pDONR-ElrA27–473 this study
pGEX-ElrA474–606 pGEX-2TK-GW carrying the elrA fragment transfered from pDONR-ElrA474–606 this study
pCMVmyc-ElrA27–723 pCMVmyc-GW carrying the elrA fragment transfered from pDONR-ElrA27–723 this study
pCMVmyc-ElrA27–473 pCMVmyc-GW carrying the elrA fragment transfered from pDONR-ElrA27–473 this study
p3flag-FHL2 pV1899-GW carrying FHL2 transfered from pDONR-FHL2 this study
pCMVHA-FHL2 pCMVHA-GW carrying FHL2 transfered from pDONR-FHL2 this study
pGEM-T-elrAΔFID pGEM-T Easy, with fragment elrAΔFID this study
pG+host9-elrAΔFID pG+host9, with EcoRI fragment of pGEM-T-elrAΔFID this study
Table 2. Strains and plasmids used in the current study.
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Identification of the minimal ElrA domain interacting with FHL2. To identify the domain of ElrA 
involved in the interaction with FHL2, several deletions of the ElrA protein (Fig. 3A) were generated using prim-
ers located at the limits of the 5 domains previously described10: the signal peptide (aa 1 to 26), the cap domain 
(aa 61 to 141), the Leucine Rich Repeat domain (aa 142 to 387), the Immunoglobulin-like domain (aa 388 to 473) 
and the WxL domain (aa 474 to 723). The 21 ElrA-fragments resulting from the amplifications were fused to the 
Gal4-DB in the pDestDB-GW vector (Table S1) and tested for their ability to interact with FHL2 fused to the 
Gal4-AD in yeasts. Interestingly, all the fragments containing the WxL domain interacted with FHL2 whereas no 
interaction was observed with the other 15 ElrA truncated mutants (Fig. 3B). The WxL domain contains 2 WxL 
motifs at position 628–630 (WxL1) and 712–714 (WxL2) and is responsible for the interaction with the peptido-
glycan and the bacterial cell surface retention of ElrA10.
We further investigated whether the two WxL motifs were responsible for the interaction with the FHL2 human 
protein. Sixteen sub-fragments of the WxL domain (aa 474 to 723) were amplified (Fig. 3A) and cloned in fusion 
with Gal4-DB. We tested the interaction with FHL2 fused to the Gal4-AD; the region spanning from the residues 
474 to 606 interacted with FHL2 defining the minimal FHL2 interaction domain (FID) of ElrA (Fig. 3C and D). 
Interestingly the 2 WxL motifs located between the aa 628 to 630 and the aa 712 to 714 are not involved in the 
interaction with FHL2. Consequently, the ElrA region that was previously called the WxL domain (aa 474 to 
723) indeed corresponds to two different functional domains: (i) FID (residues 474 to 606) and the WxL domain 
(residues 607 to 723).
GST pull-down and immunofluorescence microscopy were used as independent methods to confirm the FID/
FHL2 interaction showed by Y2H. Three GST-ElrA fusions corresponding to (i) ElrA27–723 i.e., the full-length 
protein without its signal-peptide, (ii) ElrA27–473 i.e., the N-terminal part of ElrA without the FID and the WxL 
domains and (iii) ElrA474–606 corresponding to the FID were tested with a 3Flag tagged FHL2 in a pull-down assay 
(Fig. 4A). As expected, the interaction between FHL2 and ElrA27–723 was observed. Interaction of FHL2 also 
occurred to a minor extend with ElrA474–606 that contained only the FID, were observed (Fig. 4B).
HeLa cells were transfected with plasmids encoding a HA-FHL2 and a myc-ElrA constructs coding for 
ElrA27–723 (containing FID, FID + ) or ElrA27–473 fragments (deleted for the FID, FID-). By confocal microscopy, 
a clear co-localisation was observed between FHL2 and the wild-type ElrA27–723 fusion protein, but not with the 
FID-truncated ElrA27–473 fragment. These data are consistent with an interaction of FHL2 with ElrA through the 
C-terminal part of ElrA in a cellular context (Fig. 5). Altogether these results are in agreement with a role of FID 
(aa 474 to aa 606) in the ElrA/FHL2 interaction.
In vivo importance of the ElrA FHL2 Interacting Domain. Identification of an ElrA domain that 
interacts with FHL2, led us to hypothesize that deletion of the FID domain may affect virulence as it would 
impair ElrA interaction with FHL2. To test this hypothesis and considering a potential tissue-specific interaction 
between ElrA and FHL2, we compared the virulence of a mutant strain deleted for the FID domain to the parental 
strain (OG1RF) and the ΔelrA mutant strain in two different mouse models: urinary tract (UTI) and systemic 
infection (SI) models. We constructed and tested two independent isogenic elrA mutants deleted in-frame of 
residues 474 to 606 that encompass the FHL2 interacting domain (elrAΔFID). In the UTI model (Fig. 6A), the 
Figure 2. ElrA and FHL family interaction assays. Y2H interaction matrix between ElrA and FHL1 (11050@
D04), FHL2 (31042@A08), FHL3 (11031@C01), a truncated variant of FHL3 containing 1/2 LIM2, LIM3 and 
LIM4 domains (11018@E03), FHL5 (11050@F02), GOPC (11063@H10) and CDC23 (11088@H06). Mating 
yeasts were replicated on high stringency selective media i.e., minimal medium lacking leucine, tryptophan, 
histidine and containing 5 mM of 3-aminotriazole (SC-L-W-H + 3AT) or minimal medium lacking leucine, 
tryptophan and adenine (SC-L-W-A). The yeast strains used as controls are carrying the following vectors 1, 
pPC97-CYH (DB-empty) and pPC86 (AD-empty), 2, DB-RB1 and AD-E2F-1, 3, DB-fos and AD-jun, 4, pPC97 
(DB-empty) and pPC86 (AD-empty), 5, DB-DP1 and AD-E2F1, 6, DB-FRM-3 and AD-PKc_like.
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Figure 3. Determination of the ElrA minimal domain interacting with FHL2. (A) Schematic representation of 
ElrA with a zoom on the C-terminal region, known as the WxL domain. The forward and reverse primers used 
to generate the ElrA fragments are shown as F and R, respectively. The correspondence between the position 
of primers and the ElrA amino acids is detailed in Table S1. Symbols: SP, signal peptide, cap, cap domain, LRR, 
Leucine rich repeat domain, Ig-like, Immunoglobulin-like domain, and WxL, anchor domain with the WxL1 
and WxL2 motifs are represented as thick dark bars. (B) Y2H interaction matrix between FHL2 and the 21 
ElrA fragments generated with the primers F1 to F6 (lanes) and R1 to R6 (columns). Accordingly, the first box 
on the top left of the figure corresponds to the F1-R1 amplicon i.e. the full-length ElrA. (C) Y2H interaction 
matrix between FHL2 and the 17 ElrA fragments generated with the F6 to F6.9 and the R1 to R1.9 primers. The 
minimal FHL2 Interacting Domain (FID) spans from primers F6 to R1.6. (D) Amino acid sequence of the FID 
domain. In (B) and (C), the yeast strains used as controls are containing the following vectors 1, pPC97-CYH 
(DB-empty) and pPC86 (AD-empty), 2, DB-RB1 and AD-E2F-1, 3, DB-fos and AD-jun, 4, pPC97 (DB-empty) 
and pPC86 (AD-empty), 5, DB-DP1 and AD-E2F1, 6, DB-FRM-3 and AD-PKc_like.
Figure 4. GST-pull down assay with ElrA and FHL2. (A) Schematic representation of the ElrA protein and of 
the 3 constructs used for the pull down. 1, ElrA27–473, 2, ElrA27–723, 3, ElrA474–606. Symbols: SP, signal peptide, cap, 
cap domain, LRR, Leucine rich repeat domain, Ig-like, Immunoglobulin-like domain, FID, FHL2 interacting 
domain, WxL, WxL anchor domain with the WxL1 and WxL2 motifs. (B) Pull-down assays, Western blot. The 
M2 anti-Flag antibody was used to detect the 3Flag-FHL2 from the HEK293T cells lysate pulled down by the 
GST-ElrA27–473 (lane 1), GST-ElrA27–723 (lane 2) or GST-ElrA474–606 (lane 3). 3Flag-FHL2 lysate (input) was used 
as a positive control to check the 3Flag detection. Full-length blot is presented in Figure S2.
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ΔelrA strain exhibited a decrease of 3 log units (P = 0.0003) in kidney and of 1 log unit decrease (P = 0.00304) 
in bladder compared to the WT strain, revealing that elrA contributes to pathogenesis of E. faecalis urinary tract 
infection. Interestingly, the organ bacterial loads upon infection with elrAΔFID were intermediate between the 
values observed with the WT and those obtained with the ΔelrA-mutated strain, indicating that ElrA-FHL2 
interaction is implicated in the ElrA-dependent pathogenesis in the urinary track. We then examined the vir-
ulence of the three strains in a systemic infection model post-infection intravenously (Fig. 6B). Strain ΔelrA 
showed significantly decreased burden of the liver (~ 1 log units) and kidneys (1.5 log unit) compared to the WT 
strain. In contrast, strain elrAΔFID showed an intermediate phenotype and appeared to colonize the liver at a 
comparable level as the WT while it colonized kidneys at a significant lower level (~0.4 log units of reduction for 
each strain; P = 0.02 and P = 0.049 for the two tested strains) than the WT, supporting that elrA contributes to 
E. faecalis systemic infection and partially relies on the interaction of ElrA with FHL2. Altogether, these results 
indicated that the interaction between ElrA and FHL2 have a role in systemic and urinary infections.
Discussion
Several bacterial pathogen effectors bind host proteins to hijack the host functions for their own benefits39. In 
Gram-positive bacteria, several bacterial virulence factors are located at the pathogen surface such as the inter-
nalins of L. monocytogenes27. In this study, we selected and cloned 23 putative virulence factors of the E. faecalis 
opportunistic pathogen and tested their ability to interact with host proteins using the hORFeome v3.135, 36. We 
identified a strong interaction between the virulence factor ElrA of E. faecalis and the human protein FHL2, and 
determined the minimal interacting domain of ElrA, named FID (FHL2-Interacting Domain). In addition, we 
showed that FID is partially involved in the ElrA-dependent virulence in vivo. To our knowledge, besides interac-
tions with extracellular matrix proteins, FHL2 is the first intracellular host protein targeted by a virulence factor 
of E. faecalis.
In our Y2H experimental set-up using stringent conditions33, only strong interactions are detectable, this 
explains the low range of positive hits. In the selected surface proteins, ElrA is one of the proteins that is likely 
to have a transient interaction with the bacterial surface as its WxL domain promotes a non covalent interaction 
with the peptidoglycan10. Then ElrA could be considered both as a surface and as a secreted protein. For the 
proteins covalently bound to the bacterial surface (e.g. those with an LPxTG motif), the Y2H have shown limits 
in the discovery of surface-surface protein interactions. This could be due to the low level of posttranslational 
modifications in yeast while they are important for many cell surface proteins (e.g., O- or N-glycosylation for 
eukaryotic cell receptors40) or the absence of multimerisation in Y2H experiments while it is required for the 
Figure 5. Cellular localisation of untruncated and FID-truncated forms of ElrA and FHL2. HA-FHL2 and 
myc-ElrA were produced after transfection of HeLa cells with the pCMVHA-FHL2 and pCMVmyc-ElrA27–723 
or pCMVmyc-ElrA27–473 plasmids. A representative cell is shown for each form of myc-ElrA. In the left panels 
(A and D), is represented the localisation of the untruncated (A) and the FID-truncated ElrA (D) the FHL2 
staining (anti-HA) is represented in the middle panels (B and E), and the right panels were generated by 
merging the anti-myc and anti-HA signals (C and F). Scale bars = 10 µm. Localization of HA-tagged FHL2 (B) 
is similar (C) to the localization of an untruncated myc-ElrA (A) whereas localization of HA-tagged FHL2 (E) is 
different (F) to the localization of a truncated myc-ElrA (D).
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activity of many eukaryotic surface receptors. For example, the detection of an interaction between the bacterial 
flagellin and the TLR5 homodimer receptor is not detectable using Y2H (A. Jamet personal data). However, 
the set of entry vectors encoding E. faecalis ORFs generated in this study, provides an interesting tool of easily 
transferable inserts to Gateway compatible vectors for other applications, such as the expression of an E. faecalis 
protein fused with tags that can be used for purification or tandem affinity purification allowing the purification 
of stable complexes to identify the partners involved41 or with reporters such as the GFP, which can be used to 
localize the protein42.
ElrA is an internalin-like protein that contains a signal-peptide, a leucine-rich repeat domain followed by 
an Ig-like domain and at the C-terminal end, a WxL domain, which interacts with the bacteria peptidoglycan10. 
It was demonstrated that: i) the inactivation of elrA significantly reduced E. faecalis virulence in a peritonitis 
model and that ElrA contributed to the bacterial intracellular persistence in macrophages and increased the host 
inflammatory response by stimulating in vivo the production of interleukin-610. Overexpression of ElrA protects 
from phagocytosis in vitro and increases E. faecalis virulence a mouse peritonitis model43. It was also shown that 
elrA is the first gene of an operon poorly transcribed under laboratory growth conditions but induced in mice 
during infection10. However, so far no ElrA ligand was identified. In this study, we identified a physical interaction 
between ElrA and FHL2, a member of the four-and-a-half-LIM-only family proteins. This interaction happens in 
vitro and impacts the in vivo infectious process.
The members of the four-and-a-half-LIM-only protein family are involved in many physiological processes 
probably through their ability to interact specifically with various proteins. Due to their interacting ability, 
Figure 6. In vivo effect of the FID deletion in ElrA in two mice infection models. (A) Groups of 15 BALB/c 
mice were challenged transurethrally with the OG1RF wild-type, VE14201 ΔelrA, VE18355–3 and VE18355–4 
elrAΔFID strains. Data are expressed as the log10 colony-forming units (CFUs) recovered per gram of kidneys 
or urinary bladder homogenates collected 48 hours after the challenge. The log10 CFUs from both kidneys were 
combined and averaged. A value of 0 was assigned to the uninfected organs. Horizontal bars represent the 
geometric means. P values of less than 0.05 were considered to be significant. (B) Groups of 10 BALB/c mice 
were contrast to the ElrA-deficient strain infected with the OG1RF wild-type, VE14201 ΔelrA, VE18355–3 and 
VE18355–4 elrAΔFID strains. Data are expressed as the log10 colony-forming units (CFUs) recovered per gram 
of kidneys or liver homogenates collected 7 days after the challenge. Horizontal bars represent the geometric 
means. P values of less than 0.05 were considered to be significant.
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the LIM-only proteins and by extension all proteins containing LIM domain(s), are considered as adaptors or 
scaffolding proteins44. To date in the host-microbe interactions context, a specific interaction has been shown 
between Tax1 a protein of the human T-cell leukemia virus 1 (HTLV-1) and FHL345. Our study is the first report 
describing an interaction between a bacterial protein and a specific member of the FHL family. FHL2 has a 
strong homology with the other members of the four-and-a-half-LIM-only protein family, which includes FHL1, 
FHL3, FHL4 and FHL5. The human FHL2 amino acid sequence is 48.2% identical with FHL1, 53.4% with FHL3, 
48.4% with FHL4, and 59.1% with FHL5. Although all FHLs could promote protein-protein interactions37, we 
demonstrated that ElrA interacts specifically with FHL2. FHL2 is involved in heart physiology, bone formation, 
muscular function and placental development. In addition, FHL2 is involved in a wide range of various cellu-
lar processes such as cytoarchitecture, cell adhesion, cell survival, cell mobility, signal transduction and other 
processes through the regulation of gene expression46. FHL2 enhances the transcription of the tumor necrosis 
factor (TNF) receptor-associated factor 6 (TRAF6) through the stabilization of NF-κB after activation47. FHL2 
is enzymatically inactive but has been shown to interact with more than 100 proteins through its LIM domains48 
although, the comparison of various FHL2 partners do not allow the identification of a consensus interacting 
sequence. The FHL2 partners are components of crucial signaling pathways (protein kinases, transcription fac-
tors, receptors or receptors interacting proteins), proteins known to modulate RNA splicing, DNA replication 
and repair. The broad range of cellular partners and involvement in cellular processes make FHL2 an interesting 
target for a pathogenic bacterium to ensure its survival. However, the clear picture of the cellular mechanisms 
underlying and rising from the FHL2/ElrA interaction remains to be found.
Enterococcus are traditionally considered as commensal extracellular bacteria, during its infectious process it 
can be found intracellular within urothelial cells shed from the bladder of patients49 or surviving for long periods 
into macrophages50–53. Moreover, several laboratories showed that E. faecalis escapes the phagocytic vacuole to 
avoid lysosomal elimination51–53. At late stages of infections, intracellular E. faecalis activates phosphatidylinositol 
3-kinase signaling to block apoptotic cell death in macrophages52, 53. As FHL2 is detected in the cytoplasm, we 
could anticipate that FHL2/ElrA interaction occurs during bacterial intracellular survival. However, as ElrA is 
non-covalently attached to the bacterial peptidoglycan10, we cannot rule out the possible release of ElrA directly 
into the cytoplasm of the host cell during the early interaction steps. What are the incidences or signalling path-
ways targeted by the ElrA/FHL2 interaction remain unknown. The interaction with ElrA could even compete 
with an FHL2 interacting protein or create a new complex with additional partner(s) as it is often the case in the 
host-pathogens protein-protein interactions54. Interestingly, ElrA is not the only surface-exposed protein that is 
interacting with host cytoplasmic partners. Indeed, Listeria express at its surface 2 virulence factors implicated in 
its cytoplasmic survival: ActA (actin assembly-inducing protein) and InlK (Internalin-like protein K) that interact 
with Arp2/3 and the Major Vault Protein (MVP), respectively55. The parallel between ElrA and InlK is interesting, 
as both proteins are surface-exposed virulence factors and only expressed in vivo55. Like FHL2, MVP is implicated 
in multiple cellular processes but its precise role remains unknown. MVP is recruited at Listeria surface impair-
ing autophagic recognition and consequently leading to Listeria survival in the cytoplasm56. It is tempting to 
speculate a similar role for ElrA/FHL2 interaction as E. faecalis has been recently described to resist autophagy52. 
However the role of ElrA in E. faecalis autophagy resistance remains to be investigated.
The FHL2 Interacting Domain (FID) of ElrA is 100% conserved in all the sequenced strains of E. faecalis 
suggesting a crucial functional role of this domain. Among the 24,788 prokaryotic registered genome57, apart the 
Enterococcus genus, the FID was detected in an internalin-like protein of Weissella halotolerans exhibiting 35% of 
identity with the FID of ElrA. This W. halotolerans protein could be an ElrA-like protein as it shares 34% of iden-
tity with ElrA and contains in addition to the FID, an LRR repeat domain and a WxL domain. It is noteworthy 
that W. halotolerans is an opportunistic pathogen for the rainbow trout58.
In contrast to the ElrA-deficient strain, we did not find any difference between the wild-type and elrAΔFID 
strain in the peritoneal infection model (data not shown) suggesting that the FID is not involved in the 
ElrA-dependent virulence via this infectious entry and that probably other domains of the ElrA protein are 
important for virulence; but it also demonstrated that the FID-deleted protein is stable and functional. On the 
opposite, in the UTI model, the impairment of the interaction of ElrA with FHL2 led to a systemic infection but 
with intermediate E. faecalis burdens in mice organs compared to wild-type strain (higher counts) and the fully 
deleted elrA strain (lower counts), revealing that ElrA contributes to virulence in ascending urinary tract infec-
tion. Differences in levels of attenuation of elrAΔFID in the models of UTI and SI suggest that the interaction 
between ElrA and FHL2 is tissue-specific and that other domains of ElrA may be at least as important as the FID 
to ensure a complete virulence. This observation may be related to the expression pattern of FHL2. It is expressed 
at basal level in most of the human and mice tissues (in human:<20 fragments per kilobase of exon per million 
fragments mapped (FPKM)) but shows a higher level of expression in given tissues such as the heart muscle (516 
FPKM), the ovary (456 FPKM), the placenta (74 FPKM) and the urinary bladder (90 FPKM)59).
Altogether, our study evidenced a strong interaction between ElrA (from E. faecalis) and FHL2 (from human) 
with consequences in 2 infectious models giving new hints to decipher the mode of action of this bacterial effec-
tor. This work underlined that the involvement of ElrA in Enterococcus virulence could depend on the route of 
infection. Understanding the functional role and the significance of the interaction of ElrA of E. faecalis with 
FHL2 could provide new insights into the mechanisms of virulence of this poorly understood human pathogen.
Materials and Methods
Bacterial and yeast strains, growth conditions, plasmids and oligonucleotides. The strains used 
in this work are summarized in Table 2. Escherichia coli strains were grown at 37 °C in Luria-Bertani (LB) broth or 
agar medium supplemented with the required antibiotics: ampicillin (100 µg.mL−1), spectinomycin (100 µg.mL−1), 
erythromycin (150 µg.mL−1). E. faecalis strains were grown at 37 °C in M17 broth or agar supplemented with 
0.5% of glucose (M17G) and the required antibiotics: tetracycline (5 µg.mL−1), erythromycin (30 µg.mL−1). 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7: 4581  | DOI:10.1038/s41598-017-04875-3
Saccharomyces cerevisiae strains were grown in rich YEPD medium (yeast extract 10 g.L−1, peptone 20 g.L−1 and 
dextrose 20 g.L−1) or in synthetic complete medium (SC) lacking the amino acids (Leu, Trp and His) or nucle-
obase (Ade) corresponding to its auxotrophies. The vectors used for the constructs generated in this work are 
listed in Table 2. The plasmids and primers generated by the cloning of the 23 genes of E. faecalis strain V583 and 
the 39 deletants of the elrA gene in the pDONR and pDestDB-GW vectors are listed in Table S1.
Gateway cloning of full-length E. faecalis ORFs and partial elrA fragments. The full-length E. fae-
calis selected ORFs (EfORFs) were cloned using the Gateway system (Invitrogen) as described in Dobrijevic et al.34. 
For the Y2H experiments, all the EfORFs were transferred from the pDONR223 into the pDestDB-GW60 using 
the LR clonase II (Invitrogen) to generate the yeast vectors expressing the DB-EfORF fusion proteins. As we used 
the Gateway recombination method (Invitrogen), the attB1.1 (GGGGACAACTTTGTACAAAAAAGTTGGC) 
and attB2.1 (GGGGACAACTTTGTACAAGAAAGTTGGGTC) sequences were added to the 5′ end of each for-
ward and reverse primers, respectively. An amber stop codon in frame with the elrA sequence was incorporated 
in all reverse primers. The PCR products were then cloned in the pDONR223 as previously described34.
Construction of the 3Flag tag-FHL fusions. The FHL CDS were transferred from pDONR223 to 
the Gateway destination vector pV189961 using the LR recombination cloning, generating the p3flag-FHL2, 
p3flag-FHL3, p3flag-FHL1 and p3flag-FHL5 vectors.
High-throughput yeast two-hybrid. Yeast two-hybrid screening was performed as previously 
described33. Yeast matings were performed with Y8800 and Y8930 strains62. The pDestDB vectors carrying the 
EfORFs were transformed into the Y8930 MATα yeast and selected on solid synthetic complete (SC) medium 
lacking leucine (SC-Leu). The autoactivating baits were identified by testing the growth of the yeasts containing 
the pDESTDB-EfORFs on solid SC medium lacking leucine and histidine (SC-Leu-His) and containing 2 mM of 
3-amino-triazole (3-AT); all growing clones were not selected.
Each DB-EfORF MATα yeast strain was mated with the 12,212 human AD-ORFs pooled into 130 
mini-libraries as described by Rual et al.33 on YEPD agar. After overnight growth at 30 °C, the diploids expressing 
the GAL1::HIS3 yeast two-hybrid reporter were selected on SC-Leu-Trp-His plates containing 2 mM 3-AT63. De 
novo autoactivators were eliminated using the counter-selectable marker CYH260. Positive colonies were picked 
for PCR amplification and identification of the interacting proteins by sequencing of the AD- and DB-ORFs. The 
Human proteins found to interact with the E. faecalis proteins were then individually tested against each EfORF. 
For this purpose, we mated MATα Y8930 containing individual DB fused to Ef ORF and MATa Y8800 containing 
the vector expressing the AD fused to the interacting human candidates. The plates were incubated overnight at 
30 °C on appropriate SC minimal media to select for the expression of GAL1::HIS3 or GAL2::ADE2. To elimi-
nate the yeast background due to residual growth on the minimal media, the plates were twice velvet-cleaned as 
described63. The same procedure was used to test the interaction of ElrA fragments with FHL2. At each step of 
the interaction screening and validation procedures the following yeast control strains were spotted on the plates: 
diploids yeasts containing [1] pPC97-CYH (DB-empty) and pPC86 (AD-empty), [2] DB-RB1 and AD-E2F1, [3] 
DB-fos and AD-jun, [4] pPC97 (DB-empty) and pPC86 (AD-empty), [5] DB-DP1 and AD-E2F1, [6] DB-FRM-3 
and AD-PKc_like.
Cell culture. HEK293T cells (ATCC CRL-3216) and Hela (ATCC CCL-2) were maintained in RPMI 1640 
supplemented with 10% heat-inactivated foetal calf serum, 2 mM glutamine, 1X Non essential Amino acid, peni-
cillin (50 U/ml) and streptomycin (50 U/ml) in a humidified 5% CO2 atmosphere at 37 °C. All culture media and 
supplements were supplied by Life technologies.
GST pull-down. GST-ErlA fusion proteins (ElrA(27–473), ElrA(27–723) or ElrA(474–606)) were produced 
in E. coli ER266 and purified as previously described21. HEK293T cells were transfected with the p3flag-FHL1, 
p3flag-FHL2, p3flag-FHL3 and p3flag-FHL5 vectors using the jetPrime reagent (Polyplus) following the 
manufacturer’s instructions. The transfected cells were lysed 10 min on ice in PBS-1% Triton X100-Complete 
anti-protease cocktail (lysis buffer). Cell debris and nucleus were removed by centrifugation (at 12,000 g, 15 min). 
Then, the cell extracts (200–400 μg of proteins) were incubated overnight at 4 °C with the various GST-ElrA pro-
teins bound to the beads in the lysis buffer. After incubation, the beads were washed six times in the lysis buffer 
supplemented with 0.5 M NaCl. The original lysates (inputs) and pulled-down proteins were analyzed by Western 
blotting using the monoclonal mouse anti-FLAG M2 (Sigma-Aldrich 1:2000) or the monoclonal mouse anti-GST 
(Sigma, 1:2000) as primary antibodies and the HRP-conjugated mouse anti-human IgG as secondary antibody. 
The Amersham ECLTM Prime Western blotting detection (GE Healthcare) was used for the revelation step.
Immunofluorescence and confocal microscopy. The FHL2 CDS was transferred by LR from 
the pDONR223 to the pCMVHA-GW vector21 generating the pCMVHA-FHL2 plasmid. Similarly, the 
myc-ElrA(27–723) and myc-ElrA(27–473) were produced from the pCMVmyc-ElrA vectors generated by LR 
with pCMVmyc-GW destination vector64. The transfection in HeLa cells were performed as described21. HeLa 
cells were grown on coverslips and fixed in 3% paraformaldehyde in PBS, for 15 min. Fixed cells were washed in 
PBS and permeabilized with 0.5% Triton for 5 min. Coverslips were incubated with primary antibodies in PBS 5% 
horse serum (i.e., mouse anti-c-myc IgG1κ (clone 9E10, Roche), or rat anti-HA IgG1 (3F10, Roche)) for 30 min at 
room temperature, washed in PBS 5% horse serum and then incubated with the secondary antibodies (i.e., don-
key anti-mouse IgG conjugated to Alexa Fluor 488 (Invitrogen)), and goat anti-rat IgG conjugated to Alexa Fluor 
594 (Invitrogen). Coverslips were mounted onto glass slides using Mowiol (Polysciences). Images were acquired 
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using a Zeiss LSM510 laser scanning confocal microscope and analysed using the Zeiss Zen software (Mima2 
facilities, Jouy-en-Josas France).
Construction of the E. faecalis elrAΔFID mutants. Molecular cloning techniques and gel electro-
phoresis were performed as described previously65. To delete FID domain of the elrA gene, upstream and down-
stream regions flanking the domain were amplified by PCR using E. faecalis OG1RF genomic DNA as template, 
and the following primer pairs: (i) FIDup1 (5′-TTAGTCCGTTAGGTCAAGC-3′) and FIDup2 (5′-TTCTTTGA 
CAGGTTGGACG-3′); (ii) FIDdown1 (5′-CGTCCAACCTGTCAAAGAAAGTAGCACGACCCAATATC-3′) 
and FIDdown2 (5′-AATAGCCACGCCTAAAGTG-3′). The two fragments (803 and 815 pb) were purified and a 
second PCR using FIDup1 and FIDdown2 allowed the association of the two fragments in a single PCR product 
that was cloned in pGEM-T Easy (Promega Corporation) to generate pGEM-T-elrAΔFID. After EcoRI restric-
tion of the pGEM-T-elrAΔFID, the ΔFIDelrA fragment was cloned into EcoRI-restricted pG+host966, generating 
pG+host9-elrAΔFID. The resulting plasmid was then introduced into OG1RF. An in-frame elrAΔFID mutant 
was selected as previously described10 and the deletion of the FID domain was confirmed by sequencing of the 
chromosomal locus. The procedure was repeated a second time with another pG+host9-elrAΔFID vector to 
obtain an independent elrAΔFID mutant. The mutants were named VE18355–3 and VE18355–4 (Table 2).
In vivo infections. The mouse urinary tract infections (UTIs) experiments were performed by following the 
protocol described by Lebreton et al.67. Briefly, groups of 15 female BALB/c mice (10 weeks old; Harlan Italy Srl, 
San Pietro al Natisone, Udine, Italy) were transurethrally challenged with 1 × 104 colony-forming units (CFUs) of 
wild-type OG1RF and its derivatives mutants ΔelrA and two independent elrAΔFID mutants (Table 2). 48 hours 
after infection, bladder and kidney pair cultures were prepared from mice that had been humanely killed to deter-
mine the recovered CFUs from organ homogenates.
We used a previously well-established systemic intravenous infection (SI) model68, the strains were cultured 
as in the UTI model. A 100 μL aliquot from each strain suspension (1 × 109 bacteria/mL) was injected into the 
tail vein of each of five female BALB/c mice. Seven days after infection, mice were sacrificed, and their organs 
(kidneys and livers) were removed aseptically, weighed, and homogenized, to determine the recovered CFUs. 
The experiments for each animal model were made in triplicate, and comparison among the organ counts was 
performed by use of an unpaired t test.
Mice were observed twice daily for morbidity and mortality, and any mice that exhibited noticeable morbidity 
(i.e., lethargy, scruffy coats) were euthanized immediately by CO2 inhalation. In addition, to minimize animal 
suffering and distress during the intraurethral catheterization, mice were anesthetized by isoflurane inhalation.
Statement. All methods were performed in accordance with the relevant guidelines and regulations.
The mouse experiments were approved by the Institutional Animal Use and Care Committee at the Università 
Cattolica del Sacro Cuore, Rome, Italy (permit number BB21, 04/07/2012), and authorized by the Italian Ministry 
of Health, according to the Legislative Decree 116/92, which implemented the European Directive 86/609/EEC 
on laboratory animal protection in Italy. Animal welfare was routinely checked by veterinarians of the Service for 
Animal Welfare.
References
 1. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65, doi:10.1038/
nature08821 (2010).
 2. Bar, K., Wisplinghoff, H., Wenzel, R. P., Bearman, G. M. & Edmond, M. B. Systemic inflammatory response syndrome in adult 
patients with nosocomial bloodstream infections due to enterococci. BMC infectious diseases 6, 145, doi:10.1186/1471-2334-6-145 
(2006).
 3. Agudelo Higuita, N. I. & Huycke, M. M. In Enterococci: From Commensals to Leading Causes of Drug Resistant Infection (eds M. S. 
Gilmore, D. B. Clewell, Y. Ike & N. Shankar) (Massachusetts Eye and Ear Infirmary, 2014).
 4. Arias, C. A. & Murray, B. E. The rise of the Enterococcus: beyond vancomycin resistance. Nature reviews. Microbiology 10, 266–278, 
doi:10.1038/nrmicro2761 (2012).
 5. Hollenbeck, B. L. & Rice, L. B. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 3, 421–433, doi:10.4161/
viru.21282 (2012).
 6. Riboulet, E. et al. Relationships between oxidative stress response and virulence in Enterococcus faecalis. Journal of molecular 
microbiology and biotechnology 13, 140–146, doi:10.1159/000103605 (2007).
 7. Fisher, K. & Phillips, C. The ecology, epidemiology and virulence of Enterococcus. Microbiology (Reading, England) 155, 1749–1757, 
doi:10.1099/mic.0.026385-0 (2009).
 8. Rince, A. et al. Physiological and molecular aspects of bile salt response in Enterococcus faecalis. International journal of food 
microbiology 88, 207–213 (2003).
 9. Torelli, R. et al. The PavA-like fibronectin-binding protein of Enterococcus faecalis, EfbA, is important for virulence in a mouse 
model of ascending urinary tract infection. The Journal of infectious diseases 206, 952–960, doi:10.1093/infdis/jis440 (2012).
 10. Brinster, S. et al. Enterococcal leucine-rich repeat-containing protein involved in virulence and host inflammatory response. 
Infection and immunity 75, 4463–4471, doi:10.1128/iai.00279-07 (2007).
 11. Schlievert, P. M. et al. Aggregation and binding substances enhance pathogenicity in rabbit models of Enterococcus faecalis 
endocarditis. Infection and immunity 66, 218–223 (1998).
 12. Rich, R. L. et al. Ace is a collagen-binding MSCRAMM from Enterococcus faecalis. The Journal of biological chemistry 274, 
26939–26945 (1999).
 13. Schluter, S. et al. The high biofilm-encoding Bee locus: a second pilus gene cluster in Enterococcus faecalis? Current microbiology 59, 
206–211, doi:10.1007/s00284-009-9422-y (2009).
 14. Nallapareddy, S. R. et al. Conservation of Ebp-type pilus genes among Enterococci and demonstration of their role in adherence of 
Enterococcus faecalis to human platelets. Infection and immunity 79, 2911–2920, doi:10.1128/iai.00039-11 (2011).
 15. Sillanpaa, J. et al. A family of fibrinogen-binding MSCRAMMs from Enterococcus faecalis. Microbiology (Reading, England) 155, 
2390–2400, doi:10.1099/mic.0.027821-0 (2009).
www.nature.com/scientificreports/
1 2Scientific RepoRts | 7: 4581  | DOI:10.1038/s41598-017-04875-3
 16. Bhatty, M. et al. Enterococcus faecalis pCF10-encoded surface proteins PrgA, PrgB (aggregation substance) and PrgC contribute to 
plasmid transfer, biofilm formation and virulence. Molecular microbiology 95, 660–677, doi:10.1111/mmi.12893 (2015).
 17. Sussmuth, S. D. et al. Aggregation substance promotes adherence, phagocytosis, and intracellular survival of Enterococcus faecalis 
within human macrophages and suppresses respiratory burst. Infection and immunity 68, 4900–4906 (2000).
 18. Rozdzinski, E., Marre, R., Susa, M., Wirth, R. & Muscholl-Silberhorn, A. Aggregation substance-mediated adherence of Enterococcus 
faecalis to immobilized extracellular matrix proteins. Microbial pathogenesis 30, 211–220, doi:10.1006/mpat.2000.0429 (2001).
 19. Nallapareddy, S. R., Qin, X., Weinstock, G. M., Hook, M. & Murray, B. E. Enterococcus faecalis adhesin, ace, mediates attachment to 
extracellular matrix proteins collagen type IV and laminin as well as collagen type I. Infection and immunity 68, 5218–5224 (2000).
 20. Nielsen, H. V. et al. Pilin and sortase residues critical for endocarditis- and biofilm-associated pilus biogenesis in Enterococcus 
faecalis. Journal of bacteriology 195, 4484–4495, doi:10.1128/jb.00451-13 (2013).
 21. de Barsy, M. et al. Identification of a Brucella spp. secreted effector specifically interacting with human small GTPase Rab2. Cellular 
microbiology 13, 1044–1058, doi:10.1111/j.1462-5822.2011.01601.x (2011).
 22. Mukhtar, M. S. et al. Independently evolved virulence effectors converge onto hubs in a plant immune system network. Science (New 
York, N.Y.) 333, 596–601, doi:10.1126/science.1203659 (2011).
 23. Calderwood, M. A. et al. Epstein-Barr virus and virus human protein interaction maps. Proceedings of the National Academy of 
Sciences of the United States of America 104, 7606–7611, doi:10.1073/pnas.0702332104 (2007).
 24. de Chassey, B. et al. Hepatitis C virus infection protein network. Molecular systems biology 4, 230, doi:10.1038/msb.2008.66 (2008).
 25. Simonis, N. et al. Host-pathogen interactome mapping for HTLV-1 and −2 retroviruses. Retrovirology 9, 26, doi:10.1186/1742-4690-
9-26 (2012).
 26. Mairiang, D. et al. Identification of new protein interactions between dengue fever virus and its hosts, human and mosquito. PloS 
one 8, e53535, doi:10.1371/journal.pone.0053535 (2013).
 27. Bierne, H. & Cossart, P. Listeria monocytogenes surface proteins: from genome predictions to function. Microbiology and molecular 
biology reviews: MMBR 71, 377–397, doi:10.1128/mmbr.00039-06 (2007).
 28. Pizarro-Cerda, J., Kuhbacher, A. & Cossart, P. Entry of Listeria monocytogenes in mammalian epithelial cells: an updated view. Cold 
Spring Harbor perspectives in medicine 2, doi:10.1101/cshperspect.a010009 (2012).
 29. Yamaguchi, M., Terao, Y. & Kawabata, S. Pleiotropic virulence factor - Streptococcus pyogenes fibronectin-binding proteins. Cellular 
microbiology 15, 503–511, doi:10.1111/cmi.12083 (2013).
 30. Keskin, O., Gursoy, A., Ma, B. & Nussinov, R. Principles of protein-protein interactions: what are the preferred ways for proteins to 
interact? Chemical reviews 108, 1225–1244, doi:10.1021/cr040409x (2008).
 31. Stynen, B., Tournu, H., Tavernier, J. & Van Dijck, P. Diversity in genetic in vivo methods for protein-protein interaction studies: from 
the yeast two-hybrid system to the mammalian split-luciferase system. Microbiology and molecular biology reviews: MMBR 76, 
331–382, doi:10.1128/mmbr.05021-11 (2012).
 32. Voth, D. E. ThANKs for the repeat: Intracellular pathogens exploit a common eukaryotic domain. Cellular logistics 1, 128–132, 
doi:10.4161/cl.1.4.18738 (2011).
 33. Rual, J. F. et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173–1178, 
doi:10.1038/nature04209 (2005).
 34. Dobrijevic, D. et al. High-throughput system for the presentation of secreted and surface-exposed proteins from Gram-positive 
bacteria in functional metagenomics studies. PloS one 8, e65956, doi:10.1371/journal.pone.0065956 (2013).
 35. Rual, J. F. et al. Human ORFeome version 1.1: a platform for reverse proteomics. Genome research 14, 2128–2135, doi:10.1101/
gr.2973604 (2004).
 36. Lamesch, P. et al. hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics 89, 
307–315, doi:10.1016/j.ygeno.2006.11.012 (2007).
 37. Shathasivam, T., Kislinger, T. & Gramolini, A. O. Genes, proteins and complexes: the multifaceted nature of FHL family proteins in 
diverse tissues. Journal of cellular and molecular medicine 14, 2702–2720, doi:10.1111/j.1582-4934.2010.01176.x (2010).
 38. Morgan, M. J. & Madgwick, A. J. The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle. Biochemical and 
biophysical research communications 255, 245–250, doi:10.1006/bbrc.1999.0179 (1999).
 39. Hicks, S. W. & Galan, J. E. Exploitation of eukaryotic subcellular targeting mechanisms by bacterial effectors. Nature reviews. 
Microbiology 11, 316–326, doi:10.1038/nrmicro3009 (2013).
 40. Walsh, C. Posttranslational Modification of Proteins: Expanding Nature’s Inventory: Roberts and Compagny Publishers. (2006).
 41. Rigaut, G. et al. A generic protein purification method for protein complex characterization and proteome exploration. Nature 
biotechnology 17, 1030–1032, doi:10.1038/13732 (1999).
 42. Dotreppe, D., Mullier, C., Letesson, J. J. & De Bolle, X. The alkylation response protein AidB is localized at the new poles and 
constriction sites in Brucella abortus. BMC microbiology 11, 257, doi:10.1186/1471-2180-11-257 (2011).
 43. Cortes-Perez, N. G. et al. Overexpression of Enterococcus faecalis elr operon protects from phagocytosis. BMC microbiology 15, 112, 
doi:10.1186/s12866-015-0448-y (2015).
 44. Kadrmas, J. L. & Beckerle, M. C. The LIM domain: from the cytoskeleton to the nucleus. Nature reviews. Molecular cell biology 5, 
920–931, doi:10.1038/nrm1499 (2004).
 45. McCabe, A., Hashimoto, K., Hall, W. W. & Sheehy, N. The four and a half LIM family members are novel interactants of the human 
T-cell leukemia virus type 1 Tax oncoprotein. Journal of virology 87, 7435–7444, doi:10.1128/jvi.00070-13 (2013).
 46. Kleiber, K., Strebhardt, K. & Martin, B. T. The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. 
Anticancer research 27, 55–61 (2007).
 47. Dahan, J. et al. LIM-only protein FHL2 activates NF-kappaB signaling in the control of liver regeneration and hepatocarcinogenesis. 
Molecular and cellular biology 33, 3299–3308, doi:10.1128/mcb.00105-13 (2013).
 48. Johannessen, M., Moller, S., Hansen, T., Moens, U. & Van Ghelue, M. The multifunctional roles of the four-and-a-half-LIM only 
protein FHL2. Cellular and molecular life sciences: CMLS 63, 268–284, doi:10.1007/s00018-005-5438-z (2006).
 49. Horsley, H. et al. Enterococcus faecalis subverts and invades the host urothelium in patients with chronic urinary tract infection. PloS 
one 8, e83637, doi:10.1371/journal.pone.0083637 (2013).
 50. Baldassarri, L. et al. Glycosaminoglycans mediate invasion and survival of Enterococcus faecalis into macrophages. The Journal of 
infectious diseases 191, 1253–1262, doi:10.1086/428778 (2005).
 51. Gentry-Weeks, C. R., Karkhoff-Schweizer, R., Pikis, A., Estay, M. & Keith, J. M. Survival of Enterococcus faecalis in mouse peritoneal 
macrophages. Infection and immunity 67, 2160–2165 (1999).
 52. Zou, J. & Shankar, N. The opportunistic pathogen Enterococcus faecalis resists phagosome acidification and autophagy to promote 
intracellular survival in macrophages. Cellular microbiology 18, 831–843, doi:10.1111/cmi.12556 (2016).
 53. Zou, J. & Shankar, N. Enterococcus faecalis infection activates phosphatidylinositol 3-kinase signaling to block apoptotic cell death 
in macrophages. Infection and immunity 82, 5132–5142, doi:10.1128/iai.02426-14 (2014).
 54. LaRock, D. L., Chaudhary, A. & Miller, S. I. Salmonellae interactions with host processes. Nature reviews. Microbiology 13, 191–205, 
doi:10.1038/nrmicro3420 (2015).
 55. Dortet, L., Mostowy, S. & Cossart, P. Listeria and autophagy escape: involvement of InlK, an internalin-like protein. Autophagy 8, 
132–134, doi:10.4161/auto.8.1.18218 (2012).
 56. Dortet, L. et al. Recruitment of the major vault protein by InlK: a Listeria monocytogenes strategy to avoid autophagy. PLoS pathogens 
7, e1002168, doi:10.1371/journal.ppat.1002168 (2011).
www.nature.com/scientificreports/
13Scientific RepoRts | 7: 4581  | DOI:10.1038/s41598-017-04875-3
 57. Tatusova, T., Ciufo, S., Fedorov, B., O’Neill, K. & Tolstoy, I. RefSeq microbial genomes database: new representation and annotation 
strategy. Nucleic acids research 42, D553–559, doi:10.1093/nar/gkt1274 (2014).
 58. Liu, J. Y., Li, A. H., Ji, C. & Yang, W. M. First description of a novel Weissella species as an opportunistic pathogen for rainbow trout 
Oncorhynchus mykiss (Walbaum) in China. Veterinary microbiology 136, 314–320, doi:10.1016/j.vetmic.2008.11.027 (2009).
 59. Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science (New York, N.Y.) 347, 1260419, doi:10.1126/
science.1260419 (2015).
 60. Vidalain, P. O., Boxem, M., Ge, H., Li, S. & Vidal, M. Increasing specificity in high-throughput yeast two-hybrid experiments. 
Methods (San Diego, Calif.) 32, 363–370, doi:10.1016/j.ymeth.2003.10.001 (2004).
 61. Braun, P. et al. An experimentally derived confidence score for binary protein-protein interactions. Nature methods 6, 91–97, 
doi:10.1038/nmeth.1281 (2009).
 62. Yu, H. et al. High-quality binary protein interaction map of the yeast interactome network. Science (New York, N.Y.) 322, 104–110, 
doi:10.1126/science.1158684 (2008).
 63. Walhout, A. J. & Vidal, M. High-throughput yeast two-hybrid assays for large-scale protein interaction mapping. Methods (San 
Diego, Calif.) 24, 297–306, doi:10.1006/meth.2001.1190 (2001).
 64. Henry, T. et al. The Salmonella effector protein PipB2 is a linker for kinesin-1. Proceedings of the National Academy of Sciences of the 
United States of America 103, 13497–13502, doi:10.1073/pnas.0605443103 (2006).
 65. Sambrook, J. & Russell, D. W. Molecular cloning: a laboratory manual. 3rd ed. ed. Cold Spring Harbor, N.Y.: Cold Spring Harbor 
Laboratory (2001).
 66. Maguin, E., Duwat, P., Hege, T., Ehrlich, D. & Gruss, A. New thermosensitive plasmid for gram-positive bacteria. Journal of 
bacteriology 174, 5633–5638 (1992).
 67. Lebreton, F. et al. ace, Which encodes an adhesin in Enterococcus faecalis, is regulated by Ers and is involved in virulence. Infection 
and immunity 77, 2832–2839, doi:10.1128/iai.01218-08 (2009).
 68. Michaux, C. et al. SlyA is a transcriptional regulator involved in the virulence of Enterococcus faecalis. Infection and immunity 79, 
2638–2645, doi:10.1128/iai.01132-10 (2011).
 69. Nallapareddy, S. R. et al. Endocarditis and biofilm-associated pili of Enterococcus faecalis. The Journal of clinical investigation 116, 
2799–2807, doi:10.1172/jci29021 (2006).
 70. Singh, K. V., La Rosa, S. L., Somarajan, S. R., Roh, J. H. & Murray, B. E. The fibronectin-binding protein EfbA contributes to 
pathogenesis and protects against infective endocarditis caused by Enterococcus faecalis. Infection and immunity 83, 4487–4494, 
doi:10.1128/iai.00884-15 (2015).
 71. Nallapareddy, S. R., Singh, K. V., Duh, R. W., Weinstock, G. M. & Murray, B. E. Diversity of ace, a gene encoding a microbial surface 
component recognizing adhesive matrix molecules, from different strains of Enterococcus faecalis and evidence for production of 
Ace during human infections. Infection and immunity 68, 5210–5217 (2000).
 72. Creti, R. et al. Surface protein EF3314 contributes to virulence properties of Enterococcus faecalis. The International journal of 
artificial organs 32, 611–620 (2009).
 73. Sahm, D. F. et al. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrobial agents and chemotherapy 
33, 1588–1591 (1989).
 74. Dunny, G. M., Brown, B. L. & Clewell, D. B. Induced cell aggregation and mating in Streptococcus faecalis: evidence for a bacterial 
sex pheromone. Proceedings of the National Academy of Sciences of the United States of America 75, 3479–3483 (1978).
Acknowledgements
We thank the confocal microscope platforms MIMA2 (Microscopie et Imagerie des Micro-organismes, Animaux 
et Aliments). P. Serror thanks the French-Brazilian USP COFECUB project Uc Me 147/13.
Author Contributions
Conceived and designed the experiments: A.J., N.L., M.S., B.P., P.S., E.M. Performed the experiments: A.J., R.D., 
N.L., F.B., P.S. Analysed the data: A.J., N.L., M.S., B.P., P.S., E.M. Contributed discussion/reagents/materials/
analysis tools: N.G.P.-C., H.M.B., J.-C.T. Wrote the paper: A.J., N.L., P.S., E.M. All authors reviewed the 
manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-04875-3
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
